Skip to main content

An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 2 to 17 Years, with Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) Followed b

Clinical Trial Grant
Duke Scholars

Administered By

Pediatrics, Rheumatology

Awarded By

Sanofi US

Start Date

October 16, 2017

End Date

June 30, 2020
 

Administered By

Pediatrics, Rheumatology

Awarded By

Sanofi US

Start Date

October 16, 2017

End Date

June 30, 2020